logo-loader
HealthPharma & Biotech
viewAkorn, Inc.

Generic drugmaker Akorn reports 1Q earnings and revenue that beat Street estimates; stock jumps

The specialty generic drugmaker's $0.10 loss in earnings per share (EPS) trumped estimates of a $0.20 loss

drugs
The Illinois-based company earned $166 million in revenue, beating the analysts' estimate of $153.5 million

Shares of Akorn Inc. (NASDAQ:AKRX) on Wednesday jumped more than 25% a day after the company announced first-quarter earnings and revenue that beat analysts’ estimates.

Akorn on Wednesday reported a net loss $0.10 per share when analysts expected a $0.20 loss. The company said it earned $166 million in revenue, down 10% from the prior-year quarter. But revenue beat estimates of $153.5 million. 

The specialty generic drugmaker’s stock recently traded at $4.48 a share, up 26%, on heavy volume.

READ: Akorn shares slip after court rules that Fresenius can cancel its buyout of the generic drugmaker

The Lake Forest, Illinois-based company saw its net loss widen to $82 million, compared to a net loss of $29 million in the year-ago quarter.

The company in a statement cited competition with other drug manufacturers, production delays and declines, and regulatory compliance costs for the drops in revenue and profit. 

Nevertheless, CEO Douglas Boothe said that the “results were stronger than anticipated and benefited from the resumption of full operations, improvement in product availability and strong demand across our diversified lines of business."

Akorn also provided full-year guidance, predicting net revenue in the range of $690 million to $710 million and a net loss ranging from $166 million to $151 million, according to the statement.

The company also plans to spend about $40 million on capital expenditures.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Akorn, Inc.

Price: 3.81 USD

NASDAQ:AKRX
Market: NASDAQ
Market Cap: $478.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Bacanora Lithium CEO hails completion of strategic...

Bacanora Lithium PLC's (LON:BCN) Peter Secker speaks to Proactive London's Andrew Scott following approval from the relevant Chinese authorities for Gangfeng Lithium Co Ltd to complete its strategic investment in the company. Bacanora is now in receipt of £21.9mln of funds from Ganfeng, and...

5 hours, 28 minutes ago

2 min read